Abstract
Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection.
Original language | English |
---|---|
Pages (from-to) | 1313-1318 |
Number of pages | 6 |
Journal | Infection |
Volume | 49 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2021 |
Keywords
- Bamlanivimab
- COVID-19
- Casirivimab
- Imdevimab
- Monoclonal spike antibodies
- SARS-CoV2